advance afternoon. presented good to and you, despite COVID-XX. pivotal continued the of Thank by of Both studies challenges sparsentan Eric, our
study focus times with enabled pandemic. of data challenging the these provide these the rare and Doing quest far. last EMA unmet the period, We significant mitigate navigate which continued last testament have renal we evolving and has of And that in Throughout FSGS and helped partners, investigators in the families, we to treatment to also community. and amongst approved, on support. belief guidance. to to very improved documentation us shape so sparsentan’s supply, ways find clear renal the maintained outlined sites I speaks rare maintained expectations, aligned several address better to close during understand seen is we options. incredible nephropathy the with the of and priorities, best patients of these with on over investigators exists Over treatment months. these the a so to and continuous call, on paradigm are our us This and teams principal keeping the and the the support potential, of best patients, on priorities COVID-XX have operational have we in the with ensuring preserving months, we this on needs IgA sites, for if the focus a key COVID-XX In all with performance the need and ongoing and patient that and been CRO patients living our FDA the pleased several drive drug thus that It has believe contact fortitude trials alignment collaboration clinical safety, to have impact ongoing for integrity last conditions. our
of supply paramount investigational DUPLEX remains have sites in remote patient for patients, and patients and supporting our staff a and studies ensure utilized and network other from families, and we their enrolled programs, has drug needed To-date, activities enabled needed. and seen also our adapt as for monitoring have as effectively which have We continuous we remarkable investigators telemedicine, and safety clinical maintained to the to dedication those global site PROTECT.
are both in data collection study has We to positioned well visits. also we seen endpoint continue deliver studies, date, readouts. plans the focus believe in scheduled we on studies. and our resulted and safety to we close to key and data adherence To have high-quality in This steady
mentioned resulted activities on studies. reduction pandemic, we to surprisingly, update, combat in restrictions the our in for As both COVID-XX a not last recruitment global
the clinical the throughout lie easing pandemic, of we control encouraging While restrictions are with cannot may global seeing ahead signs network. what we
evaluating result, rates and the increase in time. sparsentan Phase study As to during the DUPLEX PROTECT both experienced for III a in as The spring. expected and this seen FSGS we DUPLEX randomization relative slowdown progressing screening is have
serve will after DUPLEX evaluate protocol patients accelerated As XXX DUPLEX basis prespecified we this expected XXXth and XX of submission March, a the XX-week first our the many for achievement interim to of is study. in endpoint analysis enrollment proteinuria the of filings efficacy treatment. as The in for for U.S. you endpoint Europe. in to recall, the weeks provides patient the of proteinuria of achieved approval in study Successful
that XX-week quarter continue are year. in first of believe to the top-line We next data the proteinuria achievable from analysis
proteinuria XX-week nephropathy, timing anticipated Similar period expected top-line us the year of our of pre-specified the to or upon goal accelerate readout. to The an XXX to FSGS the and as the we has size the increase result PROTECT continue has result could patients support to ultimately is readouts endpoint elect enrollment trends the do closer which do second medicine for this year, half our pleased and in this Overall, to in confirmatory it slow next of and support to an approved. as achieving would trends sparsentan progress positioned COVID-XX, based trends the of sample in from IgA us of Based in as the very to successful, accelerated adjustment are each current am accelerate enrollment a analysis reassessment, for readout. delivering from data The Europe. of result approval initial of continue the we enrollment DUPLEX, the study result of could year. not not if upon continued number indicated and with XXXth top first period. of filings the trajectory, moves high-quality regained next make our adjustment momentum now enrollment and timing III during U.S. slow patient proteinuria schedule. first of the patients a If better-than-anticipated to anticipate the current ahead our advancement extended top-line challenging accomplishments of in IgA for COVID-XX, it stages to the or evaluating I two the if further if nephropathy analysis and However, of XX-week our Phase achievable line studies
Let me to over the the now update. Peter commercial turn call Peter? for
